CRISPR Therapeutics AG (CRSP) Social Stream



CRISPR Therapeutics AG (CRSP): $70.60

6.81 (+10.68%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add CRSP to Watchlist
Sign Up

Industry: Biotech


Ranked

of 400

in industry

CRISPR Therapeutics AG (CRSP) Price Targets From Analysts

Use the tables below to see what analysts covering CRISPR Therapeutics AG think about its future price and what recommendations they have for investors and traders.

Date Number of Analysts Highest Target Price Lowest Target Price Average Target Price Current Price Upside Potential
2021-11-12 16 $220 $100 $160.266 $69.51 130.57%
2022-02-02 16 $220 $100 $160.692 $69.51 131.18%
2022-02-04 16 $220 $100 $158.846 $69.51 128.52%
2022-02-16 17 $220 $100 $157.714 $69.51 126.89%
2022-02-17 17 $220 $64 $154.785 $69.51 122.68%
2022-02-25 16 $220 $64 $152.461 $69.51 119.34%

The Trend in the Analyst Price Target


CRSP's average price target has moved down $5.78 over the prior 38 weeks.

CRSP reports an average of 100.38% for its upside potential over the past 45 weeks.

Date Number of Analysts Highest Target Price Lowest Target Price Average Target Price Share Price Upside Potential
2021-07-02 21 220 117 163.110 155.88 4.64%
2021-11-05 16 220 100 160.266 90.24 77.6%
2022-01-17 16 220 100 160.692 67.77 137.11%
2022-02-04 16 220 100 158.846 61.89 156.66%
2022-02-17 17 220 64 154.785 58.61 164.09%

CRSP Broker Recommendations Summary

Average Broker Rating Strong Buy Buy Hold Sell Strong Sell Analysts Issuing Recs
1.63 12 0 3 1 1 16

The Trend in the Broker Recommendations


CRSP's average broker recommendation rating improved by 0.78 over the prior 44 weeks.

The bullet points below may help you gain a better understanding of what the metrics in the price target and recommendations tables above mean for CRSP as an investment opportunity.

  • CRISPR Therapeutics AG's number of analysts covering the stock is greater than 990.66% of all US stocks.
  • CRISPR Therapeutics AG's upside potential (average analyst target price relative to current price) is higher than 1033.84% of stocks in the large market cap category.
  • To contextualize these metrics, consider that out of Pharmaceutical Products stocks, CRISPR Therapeutics AG's average analyst price target is greater than 1004.2% of them.
  • In the context of stocks in the large market cap category, CRISPR Therapeutics AG's variance in analysts' estimates is lower than -880.56% of them.

In terms of price targets and recommendations offered by analysts, the stocks in the Pharmaceutical Products industry with the ratings most similar to CRISPR Therapeutics AG are BNTX, BLUE, and BIIB.

Is CRSP a Buy, Hold or Sell? See the POWR Ratings now!


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.5319 seconds.